MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ecco-jcc/jjad203

Медицинская библиотека · Journal of Crohn's & colitis · 2024

Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.

Kapizioni Christina, Desoki Rofaida, Lam Danielle, Balendran Karthiha, Al-Sulais Eman, Subramanian Sreedhar, Rimmer Joanna E, De La Revilla Negro Juan, Pavey Holly, Pele Laetitia, Brooks Johanne, Moran Gordon W, Irving Peter M, Limdi Jimmy K, Lamb Christopher A, UK IBD BioResource Investigators, Parkes Miles, Raine Tim

СтатьяСравнительное исследованиеПеревод в очереди

Аннотация

BACKGROUND AND AIMS: This study compares the effectiveness of different biologic therapies and sequences in patients with inflammatory bowel disease [IBD] using real-world data from a large cohort with long exposure.

METHODS

Demographic, disease, treatment, and outcome data were retrieved for patients in the UK IBD BioResource. Effectiveness of treatment was based on persistence free of discontinuation or failure, analysed by Kaplan-Meier survival analysis with inverse probability of treatment weighting to adjust for differences between groups.

RESULTS

In total, 13 222 evaluable patients received at least one biologic. In ulcerative colitis [UC] first-line vedolizumab [VDZ] demonstrated superior effectiveness over 5 years compared to anti-tumour necrosis factor [anti-TNF] agents [p = 0.006]. VDZ was superior to both infliximab [IFX] and adalimumab [ADA] after ADA and IFX failure respectively [p < 0.001 and p < 0.001]. Anti-TNF therapy showed similar effectiveness when used as first-line treatment, or after failure of VDZ. In Crohn's disease [CD] we found significant differences between first-line treatments over 10 years [p = 0.045], with superior effectiveness of IFX compared to ADA in perianal CD. Non-anti-TNF biologics were superior to a second anti-TNF after first-line anti-TNF failure in CD [p = 0.035]. Patients with UC or CD experiencing TNF failure due to delayed loss of response or intolerance had superior outcomes when switching to a non-anti-TNF biologic, rather than a second anti-TNF.

CONCLUSIONS

We provide real-world evidence to guide biologic selection and sequencing in a range of common scenarios. Our findings challenge current guidelines regarding drug selection after loss of response to first anti-TNF treatment.

Для цитирования: Kapizioni Christina, Desoki Rofaida, Lam Danielle, Balendran Karthiha, Al-Sulais Eman, Subramanian Sreedhar, Rimmer Joanna E, De La Revilla Negro Juan, Pavey Holly, Pele Laetitia, Brooks Johanne, Moran Gordon W, Irving Peter M, Limdi Jimmy K, Lamb Christopher A, UK IBD BioResource Investigators, Parkes Miles, Raine Tim. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.. Journal of Crohn's & colitis. 2024. DOI: 10.1093/ecco-jcc/jjad203.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.